Celularity, Inc. (NASDAQ:CELU) Short Interest Up 40.1% in March

Celularity, Inc. (NASDAQ:CELU) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 433,481 shares, an increase of 40.1% from the February 26th total of 309,422 shares. Based on an average trading volume of 724,831 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.8% of the shares of the company are short sold.

Hedge Funds Weigh In On Celularity

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Celularity by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after acquiring an additional 176,518 shares during the period. Geode Capital Management LLC raised its holdings in shares of Celularity by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after purchasing an additional 20,876 shares during the last quarter. Yorkville Advisors Global LP acquired a new position in Celularity during the third quarter valued at $207,000. Jane Street Group LLC acquired a new position in Celularity during the fourth quarter valued at $46,000. Finally, HB Wealth Management LLC purchased a new stake in Celularity in the third quarter valued at $84,000. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Stock Up 1.7%

Shares of NASDAQ:CELU opened at $1.22 on Friday. Celularity has a 52-week low of $1.01 and a 52-week high of $4.35. The stock has a market cap of $35.18 million, a price-to-earnings ratio of -0.37 and a beta of 0.79. The business has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.61.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.